Education
About Us
Working with TipRanks
Follow Us
Iterum Therapeutics (ITRM)
:ITRM
ITRM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.72 - $3.02
Previous CloseN/A
Volume220.96K
Average Volume (3M)726.27K
Market Cap
$30.81M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Aug 05, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding42,131,330
10 Day Avg. Volume902,123
30 Day Avg. Volume726,272
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.00Price Target Upside833.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Market NeedORLYNVAH is positioned to address a significant unmet need in the UTI space for safe and effective antibiotics.
Product ApprovalORLYNVAH is the first approved orally administered penem based antibiotic and has shown superiority to conventional antibiotics in late-stage clinical trials.
Strategic PartnershipsIterum announced a Product Commercialization Agreement with Eversana Life Science Services to provide sales and commercial operations services for the upcoming launch of ORLYNVAH.
Bears Say
Financial PerformanceIterum reported 1Q25 results with a net loss of ($4.9M) and ended the period with $12.7M in cash, excluding additional financing.
Market CompetitionA key challenge for Iterum may have been the overhang of the impending approval of Glaxo's gepotidacin, which could impact market dynamics.
Iterum Therapeutics News
ITRM FAQ
What was Iterum Therapeutics’s price range in the past 12 months?
Iterum Therapeutics lowest stock price was $0.72 and its highest was $3.02 in the past 12 months.
What is Iterum Therapeutics’s market cap?
Iterum Therapeutics’s market cap is $30.81M.
When is Iterum Therapeutics’s upcoming earnings report date?
Iterum Therapeutics’s upcoming earnings report date is Aug 05, 2025 which is in 4 days.
How were Iterum Therapeutics’s earnings last quarter?
Iterum Therapeutics released its earnings results on May 13, 2025. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.04.
Is Iterum Therapeutics overvalued?
According to Wall Street analysts Iterum Therapeutics’s price is currently Undervalued.
Does Iterum Therapeutics pay dividends?
Iterum Therapeutics does not currently pay dividends.
What is Iterum Therapeutics’s EPS estimate?
Iterum Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Iterum Therapeutics have?
Iterum Therapeutics has 42,131,330 shares outstanding.
What happened to Iterum Therapeutics’s price movement after its last earnings report?
Iterum Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went down -6.931%.
Which hedge fund is a major shareholder of Iterum Therapeutics?
Currently, no hedge funds are holding shares in ITRM
Iterum Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (833.33% Upside)
$7.00 (833.33% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 10.3%
Last 30 Days ▼ 10.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.82%
12-Months-Change
Fundamentals
Return on Equity
607.06%
Trailing 12-Months
Asset Growth
68.03%
Trailing 12-Months
Company Description
Iterum Therapeutics
Iterum Therapeutics (ITRM) is a clinical-stage pharmaceutical company focused on developing innovative anti-infectives aimed at combating antibiotic-resistant pathogens. The company's primary product candidate, sulopenem, is a novel, oral and intravenous penem antibiotic intended for the treatment of multi-drug resistant infections, including those caused by Gram-negative and Gram-positive bacteria. Iterum operates within the biotechnology and pharmaceutical industry sectors, emphasizing the development and commercialization of treatments for serious bacterial infections.
ITRM Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in reducing operating and R&D expenses, extending the cash runway, and preparing for the potential market launch of ORLYNVAH. However, challenges include increased G&A expenses, the inability to secure a strategic partner, competition from new market entrants, and ongoing net losses. While there are positive steps toward commercialization, the balance of highlights and lowlights suggests a cautious outlook.Read More>ITRM Stock 12 Month Forecast
Average Price Target
$7.00
▲(833.33%Upside)
Technical Analysis
Fortress Biotech
―
Outlook Therapeutics
―
Spero Therapeutics
―
X4 Pharmaceuticals
―
Repare Therapeutics
―
Ownership Overview
1.76% Insiders
0.03% Mutual Funds
1.83% Other Institutional Investors
96.38% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---